Cubist Systematic Strategies’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-165,408
| Closed | -$9.74M | – | 2988 |
|
|
2025
Q1 | $11.7M | Buy |
+165,408
| New | +$11.1M | 0.07% | 410 |
|
|
2024
Q2 | – | Sell |
-47,222
| Closed | -$3.93M | – | 3029 |
|
|
2024
Q1 | $4.12M | Buy |
47,222
+19,796
| +72% | +$1.77M | 0.02% | 1088 |
|
|
2023
Q4 | $2.64M | Buy |
+27,426
| New | +$2.43M | 0.02% | 1309 |
|
|
2023
Q3 | – | Sell |
-199,927
| Closed | -$17.8M | – | 3360 |
|
|
2023
Q2 | $17.3M | Buy |
199,927
+171,674
| +608% | +$16.2M | 0.12% | 165 |
|
|
2023
Q1 | $2.75M | Sell |
28,253
-82,535
| -74% | -$8.56M | 0.02% | 1413 |
|
|
2022
Q4 | $11.5M | Buy |
110,788
+23,590
| +27% | +$2.21M | 0.07% | 406 |
|
|
2022
Q3 | $7.39M | Buy |
87,198
+70,579
| +425% | +$6.28M | 0.04% | 715 |
|
|
2022
Q2 | $1.38M | Sell |
16,619
-147,876
| -90% | -$11.8M | 0.01% | 2193 |
|
|
2022
Q1 | $12.7M | Buy |
164,495
+71,727
| +77% | +$6M | 0.11% | 195 |
|
|
2021
Q4 | $8.2M | Buy |
92,768
+17,652
| +23% | +$1.46M | 0.08% | 350 |
|
|
2021
Q3 | $5.81M | Sell |
75,116
-42,900
| -36% | -$3.38M | 0.07% | 392 |
|
|
2021
Q2 | $9.85M | Buy |
118,016
+40,405
| +52% | +$3.2M | 0.11% | 219 |
|
|
2021
Q1 | $5.86M | Buy |
77,611
+54,107
| +230% | +$4.42M | 0.08% | 368 |
|
|
2020
Q4 | $2.06M | Buy |
23,504
+12,866
| +121% | +$1.02M | 0.03% | 921 |
|
|
2020
Q3 | $809K | Sell |
10,638
-3,964
| -27% | -$401K | 0.01% | 1460 |
|
|
2020
Q2 | $1.8M | Sell |
14,602
-15,543
| -52% | -$1.54M | 0.03% | 859 |
|
|
2020
Q1 | $2.55M | Sell |
30,145
-1,950
| -6% | -$168K | 0.07% | 384 |
|
|
2019
Q4 | $2.71M | Sell |
32,095
-7,323
| -19% | -$553K | 0.05% | 585 |
|
|
2019
Q3 | $2.66M | Buy |
39,418
+17,058
| +76% | +$1.31M | 0.05% | 514 |
|
|
2019
Q2 | $1.92M | Buy |
22,360
+13,869
| +163% | +$1.19M | 0.04% | 703 |
|
|
2019
Q1 | $754K | Buy |
8,491
+4,151
| +96% | +$385K | 0.02% | 918 |
|
|
2018
Q4 | $370K | Sell |
4,340
-12,391
| -74% | -$1.18M | 0.02% | 1142 |
|
|
2018
Q3 | $1.62M | Buy |
16,731
+7,431
| +80% | +$742K | 0.09% | 287 |
|
|
2018
Q2 | $876K | Buy |
9,300
+8,800
| +1,760% | +$771K | 0.04% | 538 |
|
|
2018
Q1 | $41K | Sell |
500
-3,729
| -88% | -$320K | ﹤0.01% | 1713 |
|
|
2017
Q4 | $377K | Sell |
4,229
-95
| -2% | -$8.26K | 0.02% | 1091 |
|
|
2017
Q3 | $402K | Sell |
4,324
-1,714
| -28% | -$151K | 0.02% | 956 |
|
|
2017
Q2 | $548K | Buy |
6,038
+2,263
| +60% | +$206K | 0.04% | 695 |
|
|
2017
Q1 | $331K | Buy |
3,775
+3,033
| +409% | +$270K | 0.02% | 852 |
|
|
2016
Q4 | $61K | Sell |
742
-26,168
| -97% | -$2.25M | ﹤0.01% | 1557 |
|
|
2016
Q3 | $2.49M | Sell |
26,910
-15,776
| -37% | -$1.49M | 0.16% | 136 |
|
|
2016
Q2 | $3.32M | Sell |
42,686
-28,160
| -40% | -$2.39M | 0.19% | 92 |
|
|
2016
Q1 | $5.84M | Buy |
70,846
+42,299
| +148% | +$3.44M | 0.33% | 38 |
|
|
2015
Q4 | $2.99M | Sell |
28,547
-2,659
| -9% | -$278K | 0.18% | 121 |
|
|
2015
Q3 | $3.29M | Buy |
31,206
+11,307
| +57% | +$1.51M | 0.17% | 109 |
|
|
2015
Q2 | $2.72M | Sell |
19,899
-3,236
| -14% | -$401K | 0.13% | 189 |
|
|
2015
Q1 | $2.88M | Sell |
23,135
-3,065
| -12% | -$325K | 0.14% | 165 |
|
|
2014
Q4 | $2.37M | Buy |
26,200
+25,000
| +2,083% | +$2.08M | 0.13% | 189 |
|
|
2014
Q3 | $87K | Sell |
1,200
-14,243
| -92% | -$936K | 0.01% | 1562 |
|
|
2014
Q2 | $961K | Buy |
+15,443
| New | +$933K | 0.06% | 494 |
|
Other funds holding BMRN
Cubist Systematic Strategies's BMRN Position: Q2 2025 in Review
Cubist Systematic Strategies sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 165,408 shares — an estimated $9.74M sold.
Cubist Systematic Strategies first reported a position in BMRN in Q2 2014 and held it in 40 quarters. The position peaked at $17.3M in Q2 2023. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.
- Cubist Systematic Strategies reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- Cubist Systematic Strategies sold 165,408 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $9.74M.
- Cubist Systematic Strategies first reported a position in BioMarin Pharmaceuticals in Q2 2014 and held it in 40 quarters.
- Cubist Systematic Strategies's BioMarin Pharmaceuticals position peaked at $17.3M in Q2 2023.
- 581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.
Based on Cubist Systematic Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.